ArticleAnnals of medicine and surgery (2012)2025
First pediatric case of follicular dendritic cell sarcoma in the parotid gland: a case report.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Case Report of follicular dendritic cell sarcoma.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Follicular dendritic cell sarcoma (FDCS) is an extremely rare malignancy originating from antigen-presenting dendritic cells of the B-cell follicles. While typically affecting adults and occurring in lymphoid tissues such as tonsils and the Waldeyer's ring, FDCS in the parotid gland is exceptionally rare, with only five adult cases reported to date. To our knowledge, this is the first documented pediatric case of FDCS of the parotid gland. Materials and methods: We present the case of a 13-year-old male with a progressively enlarging mass in the right parotid region. Diagnostic workup included imaging (MRI and CT), biopsy, and immunohistochemical staining positive for CD21 and CD23. The patient underwent systemic chemotherapy with a CCABE regimen (cisplatin, cyclophosphamide, bleomycin, etoposide, and doxorubicin), followed by external beam radiotherapy using LINAC at 40 Gy/20 fractions. Response to treatment was monitored through serial MRI and CT imaging. Results: The patient showed significant regression of both the primary tumor and pulmonary metastases following combined chemoradiotherapy. His quality of life markedly improved, and follow-up imaging confirmed resolution of the primary lesion. However, metastatic recurrence in the lungs was later observed, though the primary site remained disease-free. The patient was restarted on the same chemotherapy regimen. Conclusion: This case represents the first known pediatric FDCS of the parotid gland and demonstrates that a combination of systemic chemotherapy and targeted radiotherapy can achieve promising results, even in metastatic disease. Long-term follow-up is required to evaluate sustained response and monitor for recurrence or late treatment complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.